Lv4
480 积分 2026-07-27 加入
Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease
3天前
已完结
Physiologically Based Pharmacokinetic (PBPK) Model Predictions of Disease Mediated Changes in Drug Disposition in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
3天前
已完结
Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models
4天前
已完结
Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
4天前
已完结
Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients with Renal Impairment
4天前
已完结
The Use of Pregnancy Physiologically Based Pharmacokinetic Modeling for Renally Cleared Drugs
4天前
已完结
Physiologically based pharmacokinetic modeling of hydroxyurea: Implications for dose adjustment in patients with renal insufficiency
4天前
已完结
Physiologically Based Pharmacokinetic Modeling of Lemborexant: Exploration of Doses for Populations with Hepatic Impairment
4天前
已完结
Quantitative characterization of drug metabolism and transport alterations in obesity with metabolic fatty liver disease: A physiologically based pharmacokinetic modelling approach
1个月前
已关闭
皖公网安备34019202002308
